Under the agreement, LTD will manufacture, register and distribute AutoGenomics' INFINITI® molecular diagnostic systems and related reagent and consumable products in China. WuXi will license the assembly and manufacturing of the INFINITI® Systems in China.

The two companies will also collaborate to develop and commercialize new testing solutions that are specifically designed for China's healthcare market.

Chinese patients, doctors and pharmaceutical companies will have more convenient access to world-leading high precision, high sensitivity and highly efficient clinical diagnostic tests.

"We believe our partnership with WuXi AppTec, with its extensive operations in China and its scientific and research and development strengths, will broaden the market for our INFINITI®platform and related genetic tests in China and lead to new and broader healthcare management solutions specifically designed for the healthcare markets in China," said Fareed Kureshy, President and CEO of AutoGenomics.

"It is a milestone event for LTD to introduce AutoGenomics' instruments and diagnostic products to the China market, and an important step forward for WuXi's in vitro diagnostic business," said Dr. Jason Liu, SVP and COO of WuXi LTD.

"WuXi has a comprehensive technology platform, extensive global network, and deep understanding of the China healthcare market. We will continue to expand our collaboration and introduce more advanced technologies to China into the future." 

The collaboration will also facilitate WuXi's mission to help China's national precision medicine initiative.

"WuXi AppTec is committed to China's healthcare advancement and national precision medicine plan through active collaboration with doctors, scientists, companies and policy makers," added Dr. Ge Li, Chairman and CEO of WuXi AppTec.

"We will continue to help advance precision medicine and personalized treatment by introducing more cutting edge technologies, accelerating science from research bench to hospital beds, and ultimately benefiting the general public."